目的 了解近10年中医药类系统评价/Meta分析的发表情况。方法 检索Cochrane Database of Systematic Reviews、 PubMed、 Web of Knowledge、CNKI、SinoMed、WanFang Data、VIP数据库及Cochrane Register、PROSPERO注册平台,纳入2015年...目的 了解近10年中医药类系统评价/Meta分析的发表情况。方法 检索Cochrane Database of Systematic Reviews、 PubMed、 Web of Knowledge、CNKI、SinoMed、WanFang Data、VIP数据库及Cochrane Register、PROSPERO注册平台,纳入2015年1月—2024年12月发表的中医药类系统评价/Meta分析文献。筛选文献并对机构、国家、期刊进行标准化处理,数据清洗后,分析文献发表的年代趋势、高频病种、高频期刊、高频院校及高被引文献等。结果 纳入文献11 174篇,涉及作者56 656人次,来源于44个国家的1 422个机构,涉及1 300种期刊及1 070个病种。发文量排名前5位的机构分别为北京中医药大学(954篇)、广州中医药大学(928篇)、中国中医科学院(537篇)、天津中医药大学(460篇)和成都中医药大学(393篇);国外院校发文量较大者集中于韩国、伊朗和澳大利亚。发文量最大的中文期刊和英文期刊分别为《中医临床研究》(332篇)和Evidence-Based Complementary and Alternative Medicine (311篇)。单人成文有282篇涉及271位作者。单篇文献最高被引323次。研究数量前3位的病种为糖尿病(267篇,2.39%)、心绞痛(214篇,1.92%)和骨关节炎(210篇,1.88%)。非药物干预措施如针灸(1265篇,11.32%)、耳穴疗法(101篇,0.90%)和太极拳(98篇,0.88%)等报道最多;单一药物干预方面,雷公藤片(76篇,0.68%)和丹红注射液(54篇,0.48%)的研究量较大。结论 系统评价/Meta分析方法在中医药领域应用广泛,发表文献保持增长态势,目前已涌现出一批活跃的学术团队、机构和期刊。近10年中文中医药类系统评价/Meta分析在糖尿病、心绞痛和骨关节炎等慢性病领域证据较多,英文对针灸等非药物疗法的研究报道较多,也出现了一些高被引文献,但仍存在研究透明度和方法学标准化等问题,今后可建立透明化和质量控制体系,进一步提升中医药循证研究的可靠性、准确性和传播力。展开更多
Objective:To explore the therapeutic effect of Bushen Yiqi Huoxue Decoction BYHD)in patients with diminished ovarian reserve(DOR).Methods:A total of 180 patients with DOR diagnosed from December2013 to December 2014 w...Objective:To explore the therapeutic effect of Bushen Yiqi Huoxue Decoction BYHD)in patients with diminished ovarian reserve(DOR).Methods:A total of 180 patients with DOR diagnosed from December2013 to December 2014 were equally assigned into progynova and duphaston(E+D)group,Zuogui Pill group and BYHD group with 60 cases in each by computerized randomization.Patients received E+D,Zuogui Pill or BYHD for 12 months,respectively.Follicle stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E_(2)),anti-Mullerian hormone(AMH),antral follicle count(AFC),ovarian volume,endometrial thickness,and the resistance indices(Rls)of ovarian arteries and uterine arteries were observed before and after treatment.Results:Nine women(4 from the E+D group,3 from the Zuogui Pill group,and 2 from the BYHD group)withdrew from the study.After 6 months,Zuogui Pill and BYHD significantly decreased FSH and LH and increased endometrial thickness and AMH(all P<0.01),BYHD also resulted in E2 elevation(P<0.05),ovary enlargement(P<0.05),AFC increase(P<0.01),and RI of ovarian arteries decrease(P<0.05).After 12 months,further improvements were observed in the Zuogui Pill and BYHD groups(all P<0.01),but BYHD showed better outcomes,with lower FSH,larger ovaries and a thicker endometrium compared with the Zuogui Pill group(all P<0.01).However,E+D only significantly increased endometrial thickness(P<0.01)and no significant improvements were observed in the RI of uterine arteries in the three groups.Conclusions:BYHD had a favorable therapeutic effect in patients with DOR by rebalancing hormone levels,promoting ovulation,and repairing the thin endometrium.The combination of tonifying Shen(Kidney),benefiting qi and activating blood circulation may be a promising therapeutic strategy for DOR.展开更多
文摘目的 了解近10年中医药类系统评价/Meta分析的发表情况。方法 检索Cochrane Database of Systematic Reviews、 PubMed、 Web of Knowledge、CNKI、SinoMed、WanFang Data、VIP数据库及Cochrane Register、PROSPERO注册平台,纳入2015年1月—2024年12月发表的中医药类系统评价/Meta分析文献。筛选文献并对机构、国家、期刊进行标准化处理,数据清洗后,分析文献发表的年代趋势、高频病种、高频期刊、高频院校及高被引文献等。结果 纳入文献11 174篇,涉及作者56 656人次,来源于44个国家的1 422个机构,涉及1 300种期刊及1 070个病种。发文量排名前5位的机构分别为北京中医药大学(954篇)、广州中医药大学(928篇)、中国中医科学院(537篇)、天津中医药大学(460篇)和成都中医药大学(393篇);国外院校发文量较大者集中于韩国、伊朗和澳大利亚。发文量最大的中文期刊和英文期刊分别为《中医临床研究》(332篇)和Evidence-Based Complementary and Alternative Medicine (311篇)。单人成文有282篇涉及271位作者。单篇文献最高被引323次。研究数量前3位的病种为糖尿病(267篇,2.39%)、心绞痛(214篇,1.92%)和骨关节炎(210篇,1.88%)。非药物干预措施如针灸(1265篇,11.32%)、耳穴疗法(101篇,0.90%)和太极拳(98篇,0.88%)等报道最多;单一药物干预方面,雷公藤片(76篇,0.68%)和丹红注射液(54篇,0.48%)的研究量较大。结论 系统评价/Meta分析方法在中医药领域应用广泛,发表文献保持增长态势,目前已涌现出一批活跃的学术团队、机构和期刊。近10年中文中医药类系统评价/Meta分析在糖尿病、心绞痛和骨关节炎等慢性病领域证据较多,英文对针灸等非药物疗法的研究报道较多,也出现了一些高被引文献,但仍存在研究透明度和方法学标准化等问题,今后可建立透明化和质量控制体系,进一步提升中医药循证研究的可靠性、准确性和传播力。
基金Supported by the 2018 Program to Guide Medicine of the Shanghai Municipal Science and Technology Commission(No.18401902200)Special Project of the China Resources Sanjiu Medical and Pharmaceutical Co.and the Obstetrics&Gynecology Special Committee,the Chinese Association for the Integration of Traditional and Western Medicine(No.CR1901FC01)。
文摘Objective:To explore the therapeutic effect of Bushen Yiqi Huoxue Decoction BYHD)in patients with diminished ovarian reserve(DOR).Methods:A total of 180 patients with DOR diagnosed from December2013 to December 2014 were equally assigned into progynova and duphaston(E+D)group,Zuogui Pill group and BYHD group with 60 cases in each by computerized randomization.Patients received E+D,Zuogui Pill or BYHD for 12 months,respectively.Follicle stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E_(2)),anti-Mullerian hormone(AMH),antral follicle count(AFC),ovarian volume,endometrial thickness,and the resistance indices(Rls)of ovarian arteries and uterine arteries were observed before and after treatment.Results:Nine women(4 from the E+D group,3 from the Zuogui Pill group,and 2 from the BYHD group)withdrew from the study.After 6 months,Zuogui Pill and BYHD significantly decreased FSH and LH and increased endometrial thickness and AMH(all P<0.01),BYHD also resulted in E2 elevation(P<0.05),ovary enlargement(P<0.05),AFC increase(P<0.01),and RI of ovarian arteries decrease(P<0.05).After 12 months,further improvements were observed in the Zuogui Pill and BYHD groups(all P<0.01),but BYHD showed better outcomes,with lower FSH,larger ovaries and a thicker endometrium compared with the Zuogui Pill group(all P<0.01).However,E+D only significantly increased endometrial thickness(P<0.01)and no significant improvements were observed in the RI of uterine arteries in the three groups.Conclusions:BYHD had a favorable therapeutic effect in patients with DOR by rebalancing hormone levels,promoting ovulation,and repairing the thin endometrium.The combination of tonifying Shen(Kidney),benefiting qi and activating blood circulation may be a promising therapeutic strategy for DOR.
